Regulatory Focus™ > News Articles > FDA, in Midst of Developing Biosimilars Policy, Seeks Permanent Medical Policy Director

FDA, in Midst of Developing Biosimilars Policy, Seeks Permanent Medical Policy Director

Posted 14 August 2014 | By Alexander Gaffney, RAC 

FDA, in Midst of Developing Biosimilars Policy, Seeks Permanent Medical Policy Director

The US Food and Drug Administration (FDA) is seeking a new director for the Center for Drug Evaluation and Research's (CDER) Office of Medical Policy (OMP).

The position has previously been held by FDA's Rachel Sherman, and is now held by Acting Director Capt. Denise Hinton. The 150-person office is influential within FDA, and describes itself as the "driving force" behind drug policy development at the agency. Hinton's agency profile notes that the office is involved with developing a new policy on biosimilars development, among other initiatives.

OMP also oversees the Office of Prescription Drug Promotion (OPDP), which regulates all pharmaceutical advertising in the US.

FDA's job posting announcements indicate the agency is looking for someone with extensive experience in legal and regulatory policy, as well as leadership skills and either an MD or PhD in "a hard science."

 

FDA / USA Jobs / USA Jobs


Categories: Regulatory News

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe